Pharmaceuticals

Kesimpta Market 2026 expanding with multiple sclerosis therapies

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Kesimpta Market In 2026 And What Value Is Projected For 2030?

The historic period’s growth was propelled by the shortcomings of conventional multiple sclerosis therapies, an increase in MS diagnosis rates, breakthroughs in monoclonal antibody science, neurologists’ adoption of B-cell targeting, and the desire for more convenient dosing.

Anticipated expansion during the forecast period is primarily driven by an increasing population affected by relapsing multiple sclerosis, greater acceptance of at-home injections, the broadening of treatment into progressive forms of multiple sclerosis, enhanced patient compliance with therapies, and a rise in healthcare investment within the field of neurology. Key developments expected during this period encompass a move towards B cell depleting therapies, a growing preference for self-administered multiple sclerosis treatments, an increase in early intervention strategies for multiple sclerosis, the escalating utilization of targeted immunotherapies, and the broadening provision of neurology care delivered in home settings.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20126&type=smp

What Drivers Are Influencing The Kesimpta Market?

The growing incidence of multiple sclerosis (MS) is anticipated to propel the Kesimpta market forward. Multiple sclerosis (MS) is a persistent autoimmune condition impacting the central nervous system, resulting in nerve fiber deterioration and symptoms such as muscle weakness, visual difficulties, and cognitive decline. The rise in MS prevalence can be linked to factors like enhanced diagnostic methods, increased public understanding, and improved reporting mechanisms. Kesimpta is prescribed for relapsing types of multiple sclerosis (MS), working by targeting B-cells to diminish relapses and impede the progression of disability. For example, as reported by Neurologia i Neurochirurgia Polska, a medical journal from Poland, in August 2025, the incidence of MS in China is increasing, with annual estimates ranging from 0.2 to 0.6 per 100,000 people. Concurrently, Turkey’s MS incidence rate was 6.2 per 100,000 people in 2022, and in Saudi Arabia, recent projections indicate MS incidence rates between 3 and 5 per 100,000 people annually. Consequently, the rising prevalence of multiple sclerosis (MS) is a significant catalyst for the Kesimpta market’s expansion.

What Are The Key Segments Of The Kesimpta Market?

The kesimpta market covered in this report is segmented –

1) By Indication: Treatment Of Rhabdomyosarcoma (RMS), Treatment Of Clinically Isolated Syndrome (CIS), Treatment Of Active Secondary Progressive Multiple Sclerosis (SPMS)

2) By Formulation: Injectable formulation, Pre-filled Syringes Or Autoinjectors

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Neurology Clinics

What Key Trends Are Influencing The Development Of The Kesimpta Market?

A primary trend within the kesimpta market centers on self-administered, targeted B-cell therapy developed for the treatment of relapsing forms of multiple sclerosis (RMS). Kesimpta’s self-administered, targeted B-cell therapy provides an effective and convenient therapeutic choice for relapsing forms of multiple sclerosis (RMS), contributing to reduced relapses and a slower progression of the disease. For instance, in April 2024, Novartis AG, a pharmaceutical company based in Switzerland, recently released six-year efficacy data for its multiple sclerosis treatment, Kesimpta (ofatumumab). This data highlighted considerable benefits for individuals with relapsing multiple sclerosis (RMS) who were recently diagnosed and treatment-naïve. This information originated from the ALITHIOS open-label extension study, which underscores the crucial role of early intervention in managing this chronic condition.

Who Are The Leading Companies Operating In The Kesimpta Market?

Major companies operating in the kesimpta market are Novartis AG

Read the full kesimpta market report here:

https://www.thebusinessresearchcompany.com/report/kesimpta-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Kesimpta Market?

North America was the largest region in the kesimpta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kesimpta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kesimpta Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20126&type=smp

Browse Through More Reports Similar to the Global Kesimpta Market 2026, By The Business Research Company

Kefir Market Report 2026

https://www.thebusinessresearchcompany.com/report/kefir-global-market-report

K Beauty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/k-beauty-products-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795